摘要
背景:变应原特异性免疫治疗(AIT)是目前唯一能够调节变态反应性疾病病程的治疗方法.虽然它已经应用了100年,整个过敏原提取物并非没有缺点:ait可引起局部和全身不良反应,并可能产生新的IgE敏化其他过敏原存在于提取物中。而且,治疗时间长(3-5年)、频繁用药和高昂的治疗费用是其他缺点。由于这些原因,我们需要更安全和更有效的ait策略。。一种很有前途的方法是使用代表变应原B或T细胞表位的合成肽。 摘要目的:综述肽免疫治疗的主要进展,从临床前模型到早期临床试验,主要集中在室内尘螨、蜂毒、猫过敏、木犀科花粉等方面。(Greek=condition or state of being) (希腊语)人的条件或状态. 结果:在广泛回顾相关文献的基础上,我们总结了肽疗法是如何改变变态反应性疾病的病程,促进过敏原耐受,从而改善过敏原的。e AIT的主要缺点。虽然所涉及的分子机制尚未完全确定,但它们似乎取决于结构、长度、肽序列和给药途径。这部小说已证明mMuno治疗可调节免疫系统,促进调节T细胞诱导和Th2抑制。 该耐受诱导电势使该治疗被称为Spire(S)合成肽免疫调节表位)。 结论:实验模型和临床试验证实了SPIRE治疗这些疾病的有效性,为变应原治疗开辟了一个新的时代。
关键词: 变态反应,免疫调节,肽免疫治疗,调节性T细胞,螺旋,T细胞表位。
Current Medicinal Chemistry
Title:New Treatments for Allergy: Advances in Peptide Immunotherapy
Volume: 25 Issue: 19
关键词: 变态反应,免疫调节,肽免疫治疗,调节性T细胞,螺旋,T细胞表位。
摘要: Background: Nowadays, allergen-specific immunotherapy (AIT) is the only treatment able to modulate the course of allergic diseases. Although it has been applied for the last 100 years, treatment with whole allergen extracts is not without its drawbacks: AIT can cause local and systemic adverse events and may produce new IgE sensitization against other allergens present in the extract. Furthermore, the lengthy treatment duration (3-5 years), frequent administration, and high cost of treatment are other disadvantages. For these reasons, there is a need for safer and more effective AIT strategies. One promising approach is the use of synthetic peptides representing the B- or T-cell epitopes of allergens.
Objective: This review summarizes the main advances in peptide immunotherapy, from preclinical models to early clinical trials, focusing on house dust mite, bee venom, cat allergy, and Oleaceae pollinosis.
Results: Following an extensive review of the relevant literature, we summarize how peptide therapies may change the course of allergic diseases and promote allergen tolerance, thereby ameliorating the main disadvantages of AIT. Although the molecular mechanisms involved are not yet fully defined, they seem to depend on structure, length, peptide sequence, and route of administration. This novel immunotherapy has been demonstrated to modulate the immune system, promoting regulatory T-cell induction and Th2 inhibition. This tolerance-inducing potential has led this therapy to be termed SPIRE (synthetic peptide immuno-regulatory epitopes).
Conclusion: Experimental models and clinical trials have demonstrated the usefulness of SPIRE treatment to cure these diseases, opening a new era in allergen therapeutics.
Export Options
About this article
Cite this article as:
New Treatments for Allergy: Advances in Peptide Immunotherapy, Current Medicinal Chemistry 2018; 25 (19) . https://dx.doi.org/10.2174/0929867325666171201114353
DOI https://dx.doi.org/10.2174/0929867325666171201114353 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Primate β-defensins - Structure, Function and Evolution
Current Protein & Peptide Science Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design High Throughput Cell-Based Screening of Biodegradable Polyanhydride Libraries
Combinatorial Chemistry & High Throughput Screening New Therapeutic Targets and Drugs for the Treatment of Asthma
Mini-Reviews in Medicinal Chemistry Dysregulation of lncRNA and circRNA Expression in Mouse Testes after Exposure to Triptolide
Current Drug Metabolism Protein C Inhibitor as an Anti-Disseminated Intravascular Coagulation Agent - Mechanism and Modification
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry Natural AD-Like Neuropathology in Octodon degus: Impaired Burrowing and Neuroinflammation
Current Alzheimer Research Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Current Pharmaceutical Design Role of Ascorbic Acid in Cardiovascular Performance During Acute Hemorrhage
Vascular Disease Prevention (Discontinued) Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Sucrose Hydrolytic Enzymes: Old Enzymes for New Uses as Biocatalysts for Medical Applications
Current Topics in Medicinal Chemistry Synthesis and Biological Activity of New Tricyclic Purine Derivatives Obtained by Intramolecular N-7 Alkylation
Letters in Drug Design & Discovery Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Current Drug Targets